Chairman, CII National Committee on Biotechnology & Managing Director
Dr Rajesh Jain is Managing Director of Panacea Biotec, a leading Biotechnology Company employing over 2,500 people and Chairman, Confederation of Indian
Industry (CII), National Committee on Biotechnology for 2018-19. Past Chairman for 2011-12 & 2012-13He is recipient of India Innovation Award in 2016 and 2015 (Top 50) by Clarivate Analytics (Formerly Thomson Reuters). Dr Jain is also member of Indian Pharmacopeia (IP) Expert Working on Vaccines and Immunosera for Human Use of in the year 2017. He is also Vice President – Indian Pharmaceutical Alliance (IPA) for 2017-19. He is also Member of Academic Council of DPSRU for three years w.e.f. Sept., 2018. Under his supervision 31 patents has been granted and 33 are under prosecution. Dr. Rajesh Jain’s commitment and actions towards making affordable vaccines for mass population across the globe were appreciated and valued by GAVI and Bill & Melinda Gates Foundation during the pledge conference in June 2011 & in January, 2015. Dr Jain led the CII Task Force on Vaccines and organized “National Conference on Vaccine Industry in India” on 10th November, 2016. Dr Jian has released two Position papers on a) CII recommendations for Guideline Changes in Vaccine Approval Procedures b) The Make in India Imperative – Position Paper on Regulatory and Policy Changes required for Sustained competitiveness of the Indian Vaccine Industry. Dr. Rajesh Jain is amongst Top 40 Global most influential persons as per the list put together by World Pharmaceutical Frontiers published in SPG Media, London.
Deputy Drugs Controller Central Drugs Standard Control Organization
Ministry of Health and Family Welfare
Chandrashekar Ranga has an Honors degree in Pharmacy from the prestigious Birla Institute of Technology and Science, Pilani and Masters in Pharmaceutical
Technology from Nagpur University. He has also Degree in law and PG Diploma in Intellectual Property Laws.
He has more than 28 years experience in Drug Control Departments of the State and Central Governments in various capacities and is currently working as Deputy Drugs Controller (India) at CDSCO, Ministry of Health and Family Welfare, Govt. of India. He is currently heading the Biological division, Intelligence Cell and e-Governance cell.
He played a key role in the signing of the Memorandum of Understanding with US FDA, UK-MHRA, Japan-PMDA, Sweden- MPA, FSSH, Russia, ANVISA, Brazil
and the BRICS group. He has also successfully conducted various workshops for the industry and the regulators in collaboration with US FDA, EMA and PMDA, Japan.
In his capacity as head of legal cell, he handled various cases at Supreme Courts and other courts and coordinated conduct of DTAB and DCC meetings. He
provided valuable contribution in drafting of the Drugs and Cosmetics Bills and other Rules.
He is nominated to National Pharmaceutical Pricing Authority to represent DCGI and continuing in the Authority since 2014 and provided valuable inputs for price fixation of various medicines.
He has been awarded “Efficient Drug regulatory Official “ in 2017 by Partnership For Safe Medicines India promoted by Consumer Online Foundation.
Prof Samir K. Brahmachari is the Academy Professor of Academy of Scientific and Innovative Research, and Chief Mentor of Open Source Drug Discovery.
He is also the Chief Mentor, Health Technology Innovations for ACCESS Health International, Inc. He is the Founder Director of CSIR – Institute of Genomics and Integrative Biology (1997-2007) and former Director General of CSIR and Secretary, DSIR, Government of India (2007-2013). He conceptualized and implemented the functional genomics research in India and the Indian Genome Variation Project. He presently mentors several startups in Genomic Medicine and Big data analytics.
He is the recipient of many national and international awards including Shanti Swarup Bhatnagar prize. He is an elected fellow of The World Academy of
Sciences, the European Society of Preventive Medicine and member of all four National Academies of Science & Engineering, India.
Department of Biotechnology, Ministry of Science & Technology
Dr Alka Sharma is currently Adviser in Medical Biotechnology Division of the Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India. After completing her Ph.D from Banaras Hindu University, she joined Institute of Genomics and Integrated Biology, Council of Scientific Research (CSIR), New Delhi as Project Scientist;As a team member, she has developed various technologies and transferred to the entrepreneurs. She has co-guided post-graduate and Doctoral Fellows for their research work. She has several international and national patents to her credit and also published research papers and articles in reputed international and national Journals; Currently, she is dealing with research and policy issues in the emerging areas of biotechnology in the Government of India such as stem cells & regenerative medicine; biomedical engineering & biodesign; medical technology innovation; National Biopharma Mission; vaccine research; public health nutrition, make in India programme, Bioclusters, etc.
She received“CSIR Technology Award for Innovation” for her work.
Co-Chairman, CII National Committee on Biotechnology & Executive Director and Chief Operating Officer
Dr Mahesh Bhalgat is Executive Director – COO of Shantha Biotechnics. As head of Industrial Operations for Shantha, he has focused his efforts on regaining the WHO-pre qualification and initiating commercial supply of Shan5, Shantha’s pentavalent vaccine. Mahesh completed his B.Pharm from the University of Mumbai in India. Following his undergraduate education, Mahesh completed his Ph.D. in Medicinal Chemistry from the University of Utah. He has spent 20 years in the United States in the field of biotechnology and biologics before returning to India in 2009. While in the United States, Mahesh worked in many different areas of the biotechnology industry in the areas of R&D, Analytical &
Process Development, Technology Transfer, Regulatory Sciences and Quality. Mahesh has experience dealing with the diversity seen in industry, working with both small and large companies in the United States such as Celera Genomics, Molecular Probes, Monsanto and Amgen. Within the biologics arena, Mahesh has worked on biotherapeutics, vaccines, agricultural biotechnology and research diagnostics. He has contributed to the submission of commercial and clinical product regulatory dossiers for biotherapeutics, achieved approvals for biotech crops and launched new research diagnostics tools. Following his return to India, Mahesh started working with Biological E Ltd. where he has contributed to the
India and WHO approval of multiple vaccine products. Mahesh joined Shantha Biotech in 2013 and became a Board Member in 2015 and since then has been leading the transformation of vaccine industrial affairs.
Dr Suresh Jadhav, M.Pharm., Ph.D. is the Executive Director of Serum Institute of India Pvt. Ltd. His 46 years technical expertise includes QC/QA/cGMP/GLP/GCP techniques, inspections of laboratories and validation of various production and quality control processes, pharma/toxicological screening of various drugs, toxins & venoms etc. & drugs pricing. He successfully led the project of development and introduction of Meningococcal A Conjugate Vaccine in Sub-Saharan African belt, the development of Seasonal & Pandemic Influenza Vaccines and also played major role in acquisition of Bilthoven Biologicals, The Netherlands. Being associated with DCVMN since its inception, Dr.Jadhav was its President for 5 years. He held the positions of GAVI Board / Alternate member as also member of GAVI PPC. He is also member on European Vaccine Initiative, FastVac, and Health Innovation in Practice Board etc. He is closely associated with various advisory committees e.g. Task Force of Sabin Vaccine Institute, WHO IVR-IVAC
and Decades of Vaccines (DoV) etc. Dr Jadhav is also affiliated with several Indian universities, AICTE, UGC, State Directorate of Technical Education etc.
Nachiket Mor has an MA and a PhD in Economics from the University of Pennsylvania; a Post-Graduate Diploma in Management from the Indian Institute of Management Ahmedabad; and a Bachelor of Science degree in Physics from the University of Bombay. He has interests in the fields of healthcare and financial services.
In healthcare, he was a member of the High-Level Expert Group on Universal Health Care, the Primary Care Task Force of the Ministry of Health and Family
Welfare, the Health Commission for the State of Himachal Pradesh, and the Task Force on Global Health at the Academy of Medicine in Washington DC. He also helped create a new model for comprehensive primary care, pioneered by SughaVazhvu Healthcare in remote rural parts of Tamil Nadu. He currently serves as the India Country Director of the Bill & Melinda Gates Foundation.
Dr Davinder Gill has served as the Chief Executive Officer at Hilleman Laboratories since 2012. Dr. Gill comes with two decades of R&D and business experience in Global Pharma and Biotech companies. At Hilleman Labs, Dr Gill is responsible for Company Strategy, Product Development, Fund Raising and Public Affairs.
Dr Gill started his career in 1998 at Millennium Pharmaceuticals in Cambridge, Massachusetts in the area of Biotherapeutics. In 2003, he moved to Wyeth,
Collegeville, Pennsylvania where he served in roles of increasing responsibility as Vice President of Biological Technologies. At Wyeth, Dr Gill was instrumental in creating and leading first-of-their-kind R&D Laboratories in Ireland and Scotland in collaboration with local governments. After the acquisition of Wyeth in 2009, Dr. Gill served as Vice President and Head, Global Biotherapeutics at Pfizer, New York where he successfully led an international team and was a member of Pfizer CEO Council. In 2012, Dr. Gill was appointed CEO at Hilleman Laboratories.
Pushpa leads the healthcare and lifesciences practice of Sathguru, a 30 year old consulting firm known for its expertise across strategy, corporate finance and innovation advisory.
Pushpa has led in the pharma and biotech segment include segment strategies for leading pharma companies for biosimilars and peptides segments, pharma
focused mid-term investment strategy for global PE fund with more than $1.5billion AUM in India, human vaccines segment strategy for a biotech company, policy advisory on preparedness for adoption of identified public health priorities and licensing transactions for phase III monoclonal antibodies for US market, microsphere drug delivery platform for peptide formulation and several 505(b) (2) assets.
Pushpa’s prior experience of about fourteen years includes leading consulting engagements in PwC and E&Y and technology transfer experience at the University of Michigan Technology Transfer Office. She has a bachelor’s degree from Osmania University (India), an MBA from the Ross School of Business at University of Michigan and is a member of the Institute of Chartered Accountants of India.
Department of Biotechnology Ministry of Science & Technology
Dr S R Rao, Senior Adviser, Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India is Ph.D in Mycology and Plant Pathology from Indian Agricultural Research Institute, New Delhi. He was visiting Scientist in Tottori University, Japan and at Waite Agricultural Experimental station, Adelaide Australia and has specialized in Molecular pathology. He served in various positions in Department of Biotechnology, Ministry of Science and Technology, Government of India since 1989 and was actively involved in several sophisticated biotech infrastructure facilities, research resources, forging bilateral collaboration with Asian and /European countries, introduction of Golden rice for research in India new beginning in veterinary biotechnology, biosecurity systems, formulation of National Biotech policies, strategic planning and investment
matters. He served/serving as member of several Technical Committees of the Government of India; Academic /research councils of Universities/institutions. Currently, responsible for regulation of genetically engineering products as scientific Member Secretary of statutory body namely “Review Committee on Genetic Manipulation (RCGM)” operational for scientific risk assessment and management under Environmental Protection Act 1986 of India.
Dr Anil Koul, prior to taking the charge of Director, CSIR-IMTech, was Senior Director & Head, Respiratory Infections Discovery group at Johnson & Johnson
based in Europe. Anil has more than 16 years of experience in pharmaceutical drug discovery and obtained his Ph.D. from Delhi University, Delhi and Max-Planck Institutein Germany. He attended a short residential program at Harvard Business School on innovation, strategy and leadership.
Dr Koul’s major achievement till date has been as a key scientist involved in discovery of Bedaquiline- the first drug for treatment of drug resistant TB
discovered in last 45 years Bedaquline has been approved in US, Europe and several high TB burden countries like India, China and South Africa. In 2013, the World Health Organization (WHO) put Bedaquiline on list of its“ Essential Medicines”.
Atin Tomar is President of CPL Biologicals Pvt. Ltd., a joint venture company formed between Cadila Pharmaceuticals Limited, India and Novavax Inc, USA in
2009. CPL Biologicals focuses on research & development, manufacturing and commercialization of Vaccines, Biologics and Diagnostics for human health.
Atin brings with him comprehensive experience in the Biotechnology (Vaccines and Biologics) industry, globally. Atin’s experience and expertise spans from
Process Development, Technology Transfer and Manufacturing Operations to Business Development, Licensing and Commercialization.
Atin completed his B.Tech (Hons) in Biotechnology and Biochemical Engineering from the Indian Institute of Technology (IIT) Kharagpur, India, MS in Biological Engineering from the University of Georgia, Athens, USA and Post-Graduate Programme in Management (MBA) in Finance and Strategy & Leadership from the Indian School of Business (ISB), Hyderabad, India.
Mr Singh is quality and compliance professional with three decades of experience in biologics and biosimilars industry. He has worked in R&D, Manufacturing and Quality domains in various leading Vaccine and Biopharmaceutical companies in India.His expertise is in establishing global quality systems, quality analytics, troubleshooting and building quality culture in organizations. He has vast experience in technology and facility evaluations, technology transfers, regulatory audits, CMC reviews, GLP and GMP Trainings and Risk Assessments.
Sunil is a Managing Director with Quadria Capital, an Asian healthcare focused private equity fund with managed assets of over US$1.6 billion. Sunil has an
extensive healthcare investment and transaction experience across the Asia-Pacific market and has been involved in some of the landmark deals in the healthcare space. In his career spanning 17+ years, Sunil has led and executed deals worth over US$ 7 billion across M&A and Capital Raise. Sunil serves on the board and committees of various healthcare companies and few prestigious institutions. Sunil is a member on CII – National Committee on Biotechnology and Member - NATHEALTH. Prior to Quadria Capital, Sunil has worked with Religare Capital Markets and PNB Gilts at various senior positions. He has a Masters Degree in International Business from Delhi School of Economics
Dr Arvind Kapur is a Ph.D. in Plant Biochemistry from Punjab Agricultural University Ludhiana and was Associate Professor in Plant Breeding for 8 years. In 1988, he joined private seed sector in a company called Proagro Seed as head Operations and R&D. As a Managing Director of Proagro- PGS a Joint ventures with leading Technology Company of Europe, promoted the “Seed Link” technology in Brassica to improve yield in oil crop. He became the Managing Director of Nunhems India, a leading subsidiary vegetable seed company of Netherland and led that company to become top company of vegetable seeds in India .He expanded the vegetable seed operation in Multi crops, Multi location research station in temperate and tropical vegetable crops. He also had additional responsibility of the R&D head of Asia Pacific of the company to established R&D centres in China, Indonesia etc
He is now Managing Director of the same Company now known as Acsen HyVeg Pvt Ltd (Formerly Rasi seeds Pvt Ltd)
Dr Arvind Kapur has been secretary general and treasurer for National seed association of India (NSAI) for five years.
Deepak Pental has been a Professor of Genetics at the University of Delhi South Campus till 2016. From 2005-10 he served as the Vice-chancellor of University of Delhi. His research interests are in breeding of oilseed mustard and cotton using both conventional and genetic engineering technologies. His group has published 94 research papers in peer reviewed journals and received a number of national and international patents. He is an elected member of the National. Academy of Agricultural Sciences, the National Academy of Sciences, the Indian Academy of Sciences and the Indian National Science Academy and recipient of many awards which include – Om Prakash Bhasin Award in 2008, FICCI award in 2010, D.Sc (hc) from the University of Nottingham in 2012, J. C. Bose Fellowship of DST in 2009 and ‘Life Time Achievement Award in Agriculture’ by Mahindra and Mahindra foundation in 2018. He is currently a CSIR-Distinguished Scientist.
Dr Usha Barwale Zehr is Director and Chief Technology Officer at Maharashtra Hybrid Seeds Company Private Limited (MAHYCO), India. She received her Ph.D.
from University of Illinois at Urbana-Champaign. Subsequent to her formal education, she worked at Purdue University in the Sorghum improvement program. For the last 20 years, she has been utilizing new technologies and tools including biotechnology for improving the quality and productivity of seeds and agriculture. In addition, Dr. Zehr serves as Director of Barwale Foundation (a nonprofit Research Foundation). She also serves on the Board of the Donald Danforth Plant Science Center and Alliance for Green Revolution in Africa.
President- South East Asia and Director - Research
Shriram Bioseed Genetics
Dr Paresh Verma is currently working as President, South East Asia and Director Research in Shriram Bioseed Genetics. Prior to joining Bioseed, he has worked in Proagro Seed Company (now Bayer Bio Science), University of Nebraska and the International Crops Research Institute for Semi Arid Tropics (ICRISAT). Dr Verma holds post graduate degrees from GB Pant University of Agriculture & Technology and the University of Nebraska.
CSIR-Institute of Genomics and Integrative Biology
Dr Anurag Agrawal is Director of the CSIR Institute of the Genomics and Integrative Biology. He graduated in medicine from the All India Institute of Medical Sciences in 1994, followed by specialization in Internal Medicine, Pulmonary Disease, and Critical Care from Baylor College of Medicine, Houston, (2003) and a PhD in physiology from Delhi University. After serving as a faculty member of the Department of Medicine at Baylor, he joined CSIR-IGIB in 2007, where he established the Centre of Excellence for Translational Research in Asthma & Lung disease (TRiAL) and the CSIR program for Effective Application of Community Health efforts through new age Information Technology (EACH-IT). His research activities include use of experimental and computational model-systems to study disease, especially asthma. He has more than 100 scientific publications, mostly original research findings communicated in high-impact journals.
Chief Operating Officer, Imperial Life Sciences Pvt. Ltd.
Founder & Chief Executive Officer, Genes2me LLP
Mr Neeraj Gupta, has been in the life sciences and molecular diagnostics business since last 2 decades at ILS with a mission to provide latest, advanced state-of-theart global technologies to the Indian scientific fraternity for research in Genomics, Cell biology, Molecular Imaging and Advanced Molecular Diagnostics.
Mr Gupta also is the Founder & CEO of Genes2Me LLP, a personalized medicine and molecular diagnostics startup, with focus of bringing advanced Molecular
diagnostic technologies for the Indian clinicians and bridging the Gap in the Advanced Molecular Diagnostics market. He runs the organization with the belief of creating a benchmark in the field of personalized healthcare particularly in the areas of Mother & Child, Oncology, Preventive Wellness & Genetic screening and provide advanced molecular diagnostic testing at an affordable pricing.
Dr Liu Muyun, Director of the National and Local Joint Engineering Laboratory of Personalized Cell Therapy, Founder of the Shenzhen Kenuo Medical Laboratory.
As a member of China National Medicine Policy Expert Committee of Xinhua Liaowang Think-tank, From 2015 to 2018, Dr Liu made constructive suggestions
on health and sustainable development in the field of cell therapy at the National People’s Congress (NPC) as well as the National Committee of the Chinese People’s Political Consultative Conference (CPPCC). Being an expert in industrial policy research, she was invited to design Strategic Emerging Industries and outline of mid-long development program for future industry by Shenzhen municipal government.As one of the founder members, Dr Liu co-founded the Chinese Journal of Cell and Stem Cell.
Pranav Anam is one of the rare founder CEO’s who have an innate ability to be able to flawlessly manage and deliver on multiple roles in business, cuttingedge technologies and being a specialist. He did his masters in Genetics from Newcastle University in and quickly climbed the ropes of the corporate ladder from being a Deputy GM to CEO below 30 years at Emprocell between 2011-2014. He played myriad roles at Emprocell from establishing the ethics board to defining operations strategy to establishing a dedicated institutional committee for Stem Cell Research and Therapy and attaining pivotal infrastructural and cooperative acquisition. Armed with this rich exposure and having been at the helm of various independent projects he set up The Gene Box in 2015. His passion for making a meaningful impact on an individual’s wellness was the motivation to create an easy to use a product called The Gene Box.
Kapil has three decades of leadership experience. He first built his career in the technology industry and was leading Sun Microsystems and then Tektronix in India. He got inspired by the Mission of Thermo Fisher (Enable our customers to make the world healthier, cleaner and safer) and how he could get the opportunity of impacting the lives of people in true sense. He now manages the business of Life Sciences Solutions Group for South Asia at Thermo Fisher and also leads all the global teams based out of Bangalore.
Kapil has a bachelor’s degree in engineering. He is also a Fulbright Fellow and completed ‘Leadership in Management’ program from Carnegie Mellon University.
Dr Panchapagesa Murali P M Murali, is the Chairman of Jananom Private limited a young start up established in Bengaluru. He previously worked as the
Managing Director of the Swiss International Company Evolva Biotech, one of the pioneering firms in biomolecular engineering in the world to generate products from microbial factories that are applied across diverse verticals from pharmaceuticals, nutraceuticals, flavours & fragrances, agriculture, veterinary, FMCG goods and defence. He was instrumental in establishing this as India’s unique public private partnership model into a CSIR institute in Hyderabad before moving the establishment to Chennai. He was one of the first in the world to build a successful pipeline for pushing “molecules to market” to reap their commercial benefits, by building a rich ecosystem of contract research institutions and public research institutions not just in India but in several other countries as well. Many of these partnerships and collaborations were also anchored by Governments in Asia for welfare of the society.
Dr Shirshendu Mukherjee, trained as a Medical Microbiologist brings with him more than 2 decades of experience in academic institutes, Pharma companies and
decade long experience in national, international philanthropic and Government funding agencies and has been instrumental in supporting the innovation ecosystem in the India and beyond.
Dr Mukherjee is currently the Mission Director of the Program Management Unit at BIRAC, formed by the partnership between the Bill & Melinda Gates Foundation, the Department of Biotechnology, Government of India and the Wellcome Trust which manages the Grand Challenges Program of the Foundation which funds a wide range of research areas from maternal and child health, infectious diseases, vaccines, point-of-care diagnostics, agricultural development, food and nutrition, sanitation and hygiene etc.
Dr Mukherjee holds Ph.D. in Microbiology, Law graduate, Advance Course in Strategy Management form IIM Kolkata and Management and Leadership course form Said Business school University of Oxford.
Dr. Prabuddha K Kundu has about 19 years of experience in research/production related to proteins. He completed his M.Tech and PhD in Biomedical Engineering from IIT-Bombay. He has been associated with scaling up pilot projects in biomanufacturing in India and South-East Asia. He cofounded Premas Biotech along with five other members. In Premas, he has been part of certain interesting solutions developed for Pharma/Biotech solutions. His primary interests are in process optimisation, and continuous process development. Apart from this, Prabuddha has great interest in learning about new technologies and start-ups. He is a core member of CII Biotechnology committee 2017 and co-chair on the Start Up India campaign. Prabuddha has 8 International patents, and more than 20 international publications.
Manohar is the MD & CEO of Stempeutics Research – a leading stem cell research and product development company in India. He earned his B.E. degree in Electronics & Communication from REC Trichy in 1977. Post that he did M.E. in Computer Science from College of Engineering, Guindy.
Manohar has transformed Stempeutics – a life science start-up from R&D to Commercialization stage with Global recognition. Stempeutics has developed an
innovative drug called “Stempeucel” for addressing major unmet medical needs in India and Globally. This drug developed by an Indian company has received many Global Recognitions. Seven countries including US & Japan has granted patent for the novelty and inventiveness of the drug. Europe has recognized this drug by granting Advanced Therapy Medicinal Product classification and Orphan Drug Designation. Recently it became the FIRST stem cell product to be approved by DCGI for conditional marketing for treating patients suffering from life threatening disease call Buerger’s Disease. Stempeutics has put India on the “World map of Regenerative Medicine”.
Dr Ramanan Thirumoorthy is Vice President - Technical at Richcore Lifesciences Pvt. Ltd, Bangalore. He has over 20 years of experience in recombinant protein biotechnology, including protein purification, structure elucidation and analytical chemistry. He started as a chemistry graduate with a masters from IIT, Madras followed by PhD in Biochemistry from University of Florida, USA. After 3 years of postdoctoral experience in the US and Canada, he moved back to India to start his R&D career in pharmaceutical industry. He has over 15 patents and publications. He currently heads the R&D at Richcore, which is involved in the development of clones and fermentation process to produce recombinant proteins for biopharma applications.